Vivatides Therapeutics Secures $54 Million to Scale Extrahepatic RNA Delivery Platform

Breaking the Liver Barrier

Vivatides Therapeutics, a biotechnology startup operating out of Suzhou and Boston, has successfully closed an oversubscribed $54 million Series A financing round. The capital injection is dedicated to advancing the company's proprietary delivery platform designed to transport RNA payloads to tissues beyond the liver. This funding milestone arrives less than a year after the company's founding, reflecting intense interest in extrahepatic targeting.

While traditional RNA drugs rely on the liver-centric GalNAc conjugation, Vivatides is developing next-generation technologies to reach underserved organs. Their platform utilizes sophisticated ligand conjugation to facilitate receptor-mediated endocytosis in non-hepatic cells. This method aims to provide the same level of specificity and safety for extrahepatic tissues that current treatments offer for liver diseases.

The company's technological suite spans both small interfering RNA (siRNA) and antisense oligonucleotides (ASO). According to company reports, they have achieved significant breakthroughs in ligand design, chemical stability, and tissue targeting. These advances have already yielded positive in vivo results, clearing the path for rapid clinical translation of several pipeline programs.

By bypassing the reliance on traditional lipid nanoparticles, Vivatides intends to minimize systemic toxicity while maximizing delivery efficiency. Their research focus includes high-prevalence chronic conditions such as hypertension and various forms of oncology. This pivot from rare genetic disorders toward mass-market diseases signifies a new era for RNA as a versatile therapeutic modality.

Founder Keming Zhou brings over 16 years of expertise in RNA-targeting therapies to lead the technical development. The financing was co-led by Qiming Venture Partners and an undisclosed leading industry fund. Proceeds will fund upcoming IND-enabling studies and the expansion of the company's global R&D infrastructure in both the US and China. Industry observers note that overcoming the delivery bottleneck is the final step in making RNA drugs as common as small molecules. Vivatides is now positioned to lead this transition through its differentiated delivery platform. The company plans to engage with value-driven partners to further scale its therapeutic reach across the globe.